Cartherics is proud to share that our CEO, Professor Alan Trounson, was recently interviewed on 10 News+ by journalists Amelia Brace and Denham Hitchcock.

In the interview, Prof. Trounson provided an in-depth look at Cartherics’ world-first immunotherapies and how this innovative science is shaping the future of treatment for some of the most difficult-to-treat diseases.

Our lead programs focus on ovarian cancer and endometriosis, two devastating and often overlooked conditions that currently have limited therapeutic options. By programming immune cells to recognise and respond to diseased cells, Cartherics aims to deliver more effective, targeted, and accessible treatments for patients who have long awaited better solutions.

Looking beyond these initial indications, Cartherics is also advancing research into immune cell therapies for:

• Triple negative breast cancer
• Pancreatic cancer
• Neurodegenerative diseases such as Alzheimer’s Disease

This reflects our commitment to broadening the impact of our cutting-edge science across a range of serious diseases.

Watch the full interview here:
https://youtu.be/XSKPzRMJiHY